Condition: Ovarian Cancer · Sponsor: University of Miami
The purpose of this study is to identify the genetic characteristic(s), specifically degree of African ancestry, and environmental characteristic(s) that appear to be related to the effects, both good and bad, that the maintenance treatment has women with ovarian cancer. In this study, an investigational medication called niraparib is being tested for the treatment of ovarian cancer. Niraparib works by blocking the ability of cancer cells to fix their genes. Cancer cells with damaged genes have a harder time growing and spreading in the body and can even die.
This description comes directly from the study's public registry record.
Matthew Schlumbrecht, MD, MPH · 305-243-2233 · mschlumbrecht@med.miami.edu
Always discuss trial participation with your own doctor first.
| Broward Health | Fort Lauderdale, Florida, United States | Recruiting |
| University of Florida Jacksonville | Jacksonville, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Ahmadu Bello University Teaching Hospital (ABUTH) | Zaria, Kaduna State, Nigeria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06412120